Publications by authors named "S Schwartzman"
Article Synopsis
- This safety analysis examines the occurrence of mucosal/cutaneous Candida infections in patients using ixekizumab (IXE) for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis.
- Data from 25 clinical studies indicated a low incidence rate of 1.2-2.0 per 100 patient-years, with most infections being mild, typically single occurrences, and largely resolved during the studies without requiring treatment discontinuation.
- Overall, the findings suggest that the risk of Candida infections with IXE is low and usually mild-to-moderate in severity, with effective management strategies in place.
Purpose: Adults with acquired communication disorders are particularly vulnerable to potential negative effects from the changes that arose during the COVID-19 pandemic. In this longitudinal study, we asked: How did the self-perceived impacts of the pandemic on adults with acquired communication disorders change over time?
Method: We developed an online survey to investigate changes in day-to-day behaviours, psychosocial elements, and communication abilities among members of a community-based stroke recovery centre in the USA. Participants included adults with aphasia or other cognitive-communication disorder from stroke or brain injury.
Article Synopsis
- Systemic immunomodulatory agents are used to treat moderate-to-severe plaque psoriasis and psoriatic arthritis, but their use before surgery may raise the risk of infections and complications.
- The study aimed to assess the risk of surgical site infections (SSI) in patients with autoimmune diseases who are on various immunomodulatory drugs and undergoing surgery.
- Findings suggest that for low-risk surgeries, many immunomodulatory treatments, such as TNF-α inhibitors and methotrexate, can be safely continued, while for more complex surgeries, a careful evaluation is recommended before continuing their use.
Background: We report long-term, end-of-study program safety outcomes from 25 randomized clinical trials (RCTs) in adult patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) [including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)] who received ≥ 1 dose of Ixekizumab (IXE) over 5 years (PsO) or up to 3 years (PsA, axSpA).
Methods: This integrated safety analysis consists of data from patients who received any dose of IXE, across 25 RCTs (17 PsO, 4 PsA, 4 axSpA). Rates of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and selected adverse events (AEs) of interest were analyzed for all pooled studies by years of therapy and overall, through March 2022.
Article Synopsis
- Psoriatic patients receiving vaccines need clear guidelines on whether to pause or maintain their systemic medications, especially for live and nonlive vaccines.
- The National Psoriasis Foundation Medical Board and experts developed 22 consensus statements recommending that most patients can continue oral and biologic therapies for nonlive vaccines, but should consider stopping methotrexate.
- For live vaccines, most therapies should be interrupted before and after vaccination, except for abatacept, and timing adjustments for vaccine administration are crucial.